← Every company
Biontech SE Patents
What Biontech SE has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
BNTX on carbonthat →Filings on file
53
Granted
0
Still pending
53
Filed under
2 names
53 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| PREPARATION AND STORAGE OF LIPOSOMAL RNA FORMULATIONS SUITABLE FOR THERAPYFiled as BIONTECH SE2026-09-23Heinrich HAAS | pending |
| IL2 AgonistsC07K 14/55, A61K 47/643, A61K 47/68, A61K 47/644, A61P 35/00, A61K 38/00, A61K 38/2013, A61K 39/0011, A61K 39/39, A61K2039/55533, C07K2319/30, C07K2319/31Filed as BioNTech SE2026-04-30Ugur Sahin | pending |
| COMBINATION THERAPY FOR CANCER TREATMENTC07K 16/2818, C07K 16/2827, A61K 47/6851, A61K 47/6849, A61K 47/6855, A61P 35/00, A61K 47/68037, A61K 47/68031, A61K 31/4725, A61K2039/505, A61K2039/507, C07K 16/22, C07K 16/2863, C07K 16/30, C07K 16/32, C07K2317/31, C07K2317/569, C07K2317/622, C07K2317/76Filed as BioNTech SE2026-04-03Ugur SAHIN | pending |
| AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLSFiled as BioNTech SE2026-01-30Ugur SAHIN | pending |
| CORONAVIRUS AND INFLUENZA IMMUNOGENIC COMBINATIONSFiled as BIONTECH SE2026-01-06ALPTEKIN GÜLER | pending |
| INTRAVAGINAL FORMULATIONS OF GARDNERELLA ENDOLYSINSA61P 31/04, A61K 38/47, A61K 31/78, A61K 33/14, A61K 38/162, A61K 47/02, A61K 47/32, A61K2300/00, C12N 9/2462Filed as BioNTech SE2025-11-06Ann-Katrin Kieninger | pending |
| ANTIBODY-DRUG CONJUGATES EMPLOYING NOVEL LINKER-PAYLOAD SYSTEMS FOR ENHANCED TARGETING OF CANCER-ASSOCIATED GLYCAN ANTIGENSA61K 47/6889, A61K 47/6843, A61K 47/6851, A61P 35/00, A61K 47/68037, A61K2039/505, C07K 16/2896, C07K2317/24, C07K2317/565, C07K2317/77, C07K2317/90, C07K2317/92, C07K2317/94Filed as BioNTech SE2025-11-04Gonçalo Bernardes | pending |
| OPTIMIZED CSP VARIANTS AND RELATED METHODSA61K 39/015, C07K 14/445, A61P 31/00, A61P 37/04, Y02A 50/30, A61K 39/00, A61K2039/53, A61K2039/55555, C12N 15/88, C12P 19/34Filed as BioNTech SE2025-10-31Thomas ZIEGENHALS | pending |
| MODULAR MULTIPLATFORM SYSTEM FOR MRNA DRUG PRODUCTIONA61K 9/1277, B01J 19/004, A61K 39/00119, A61K 39/001163, A61K 39/001156, B01D2325/02834, A61L2103/10, A61K 9/5123, A61K 9/5192, A61K 39/0011, A61K2039/53, A61K2039/55555, A61K2039/70, A61L 2/022, A61L 2/22, B01D 15/327, B01D 61/14, B01D 69/02, B01D 71/16, B01D2315/10, B01J 19/0066, B01J2219/0002, B65B 3/003, B65B 7/2857, B65B 55/10, B65B 65/003, F04B 43/12Filed as BioNTech SE2025-10-31Rainer Kröner | pending |
| METHODS AND SYSTEMS FOR MASS-SPECTROMETRY-BASED DETECTION OF NON-CANONICAL PEPTIDESFiled as BIONTECH SE2025-10-31MICHAEL STEVEN ROONEY | pending |
| FLUID PATH SYSTEM, MIXING SYSTEM, METHOD FOR MANUFACTURING A MIXTURE, AND USE OF A FLUID PATH SYSTEM AND OF A MIXING SYSTEMB01F 25/14, A61M 39/00, B01F 35/7174, B01F 35/712, A61M2039/0027Filed as BioNTech SE2025-10-03Heinrich HAAS | pending |
| METHODS FOR PREDICTING AND IMPROVING THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND METHODS FOR CANCER PROGNOSISG01N 33/5759, G01N 33/57525, G01N2333/705, G01N2800/52, G01N2800/7028Filed as BioNTech SE2025-09-30Francesco DE SANCTIS | pending |
| STABILIZED NUCLEIC ACID COMPOSITIONS AND METHODS FOR PREPARING, STORING AND USING THE SAMEA61K 9/5123, A61P 31/14, A61K 9/0019, A61K 31/7105, A61K 31/7115, A61K 47/02, A61K 47/16, A61K 47/183, A61K 47/22, A61K 47/24, A61K 47/26, A61K 47/28Filed as BioNTech SE2025-09-23Heinrich HAAS | pending |
| LINKER SEQUENCE POTENCY ASSAYS FOR MULTIPLE CODING NUCLEIC ACIDSC12Q 1/6804, C12Q 1/6806, C12Q 1/37, C12Q 1/6809, C12Q 1/6876, C12Q2600/136, C12Y 304/21004, C12Q2521/537, C12Q2525/149, C12Q2537/143, C12Q2545/114, C12Q2565/627Filed as BioNTech SE2025-08-27Daniel Abram Rothenberg | pending |
| STING AGONISTS CONTAINING HYDRAZIDE, HYDRAZINE, AND HYDROXAMIC ACID FUNCTIONAL GROUPSC07D 401/14, C07D 413/14, A61P 35/00, A61K 31/4184, A61K 31/428, A61K 31/429, A61K 31/437, A61K 31/438, A61K 31/496, A61K 31/5377, C07D 403/14, C07D 417/12, C07D 417/14, C07D 471/04, C07D 513/04Filed as BioNTech SE2025-08-26Zhengxin Dong | pending |
| STING AGONISTS CONTAINING BENZYLIC ALCOHOL AND BENZYLIC AMINE FUNCTIONAL GROUPSFiled as BioNTech SE2025-08-26Ilga Krimmelbein | pending |
| Methods for Providing Single-Stranded RNAC12N 15/10, C12N 15/101, A61P 37/02, A61P 31/00, A61P 31/12, A61P 31/04, A61P 29/00, A61P 31/10, A61P 35/00, A61K 48/00, C12N 15/11Filed as BIONTECH SE2025-08-22Markus Baiersdorfer | pending |
| VACCINE MIXING METHOD, SYRINGE AND SYSTEMA61K 39/215, A61J 1/2048, A61K 39/12, A61K 39/145, A61K2039/5252, A61K2039/53, A61K2039/70Filed as BioNTech SE2025-08-21Alexander Muik | pending |
| RNA Particles Comprising PolysarcosineA61K 47/6911, A61K 47/645, A61K 47/6935, A61K 47/543, A61K 47/6929, A61K 47/62, A61K 47/6939, A61K 9/127, A61K 9/5146, A61K 47/18, A61K 47/24, A61K 47/28, A61K 48/0025, A61K 48/0041, C08G 69/10, C12N 15/85, C12N 15/88Filed as BIONTECH SE2025-08-21Matthias BARZ | pending |
| FLUID HANDLING SYSTEM AND METHODB01F 25/4337, B01F 23/45Filed as BioNTech SE2025-08-06Sebastian HÖRNER | pending |
| COMPOSITIONS AND METHODSA61K 9/1272, A61K 9/5123, A61P 35/00, A61K 9/0019, A61K 9/127, A61K 9/1271, A61K 9/1277, A61K 9/145, A61K 9/19, A61K 9/5192, A61K 31/7105, A61K 39/00, A61K 39/0011, A61K 39/39, A61K 47/12, A61K 47/18, A61K 47/183, A61K 47/22, A61K 47/24, A61K 47/26, A61K 47/28, A61K2039/53, A61K2039/55555Filed as BioNTech SE2025-07-25Heeralal Bassi | pending |
| PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF HERPES SIMPLEX VIRUS GLYCOPROTEIN C, GLYCOPROTEIN D, AND GLYCOPROTEIN E ANTIGENS AND RELATED METHODSA61K 39/12, A61K 39/245, A61P 31/22, A61K 39/295, A61K2039/53, A61K2039/54, A61K2039/545, A61K2039/55555, A61K2039/575, C12N2710/16622, C12N2710/16634Filed as BioNTech SE2025-07-25Alptekin Güler | pending |
| COMPOSITIONS AND METHODSA61K 9/1272, A61K 9/5123, A61P 35/00, A61K 9/0019, A61K 9/127, A61K 9/1271, A61K 9/1277, A61K 9/145, A61K 9/19, A61K 9/5192, A61K 31/7105, A61K 39/00, A61K 39/0011, A61K 39/39, A61K 47/12, A61K 47/18, A61K 47/183, A61K 47/22, A61K 47/24, A61K 47/26, A61K 47/28, A61K2039/53, A61K2039/55555Filed as BioNTech SE2025-07-25Kaushik Thanki | pending |
| COMPOSITIONS AND METHODSA61K 9/1272, A61K 9/5123, A61P 35/00, A61K 9/0019, A61K 9/127, A61K 9/1271, A61K 9/1277, A61K 9/145, A61K 9/19, A61K 9/5192, A61K 31/7105, A61K 39/00, A61K 39/0011, A61K 39/39, A61K 47/12, A61K 47/18, A61K 47/183, A61K 47/22, A61K 47/24, A61K 47/26, A61K 47/28, A61K2039/53, A61K2039/55555Filed as BioNTech SE2025-07-25Kaushik Thanki | pending |
| BINDING AGENTS BINDING TO EPCAM AND CD137C07K 16/30, A61P 35/00, A61K2039/505, C07K 16/2878, C07K2317/31, C07K2317/35, C07K2317/52, C07K2317/56, C07K2317/71, C07K2317/73, C07K2317/732, C07K2317/734, C07K2317/75, C07K2317/92Filed as BioNTech SE2025-07-16Andreea IOAN | pending |
| VACCINE COMPOSITION FOR ELICITING AN EBV-SPECIFIC CD8+ T CELL RESPONSEFiled as BIONTECH SE2025-07-11DAPHNE KAXIRAS | pending |
| HSV ANTIGEN FRAGMENTS AND RELATED METHODSFiled as BIONTECH SE2025-07-11RAQUEL MARISKA FURTADO | pending |
| RNA COMPOSITIONS TARGETING HIVC07K 16/1145, C07K 16/114, A61K2039/505, C07K2317/52, C07K2317/524, C07K2317/526, C07K2317/53, C07K2317/622, C07K2317/76, C07K2317/94Filed as BioNTech SE2025-06-27Valentin Le Douce | pending |
| COMPOSITIONA61K 9/1272, A61K 9/5123, A61K 48/0041, A61K 9/1277, A61K 9/5192, A61K 31/7105, A61K 31/711, A61K 39/0011, A61K2039/53, A61K2039/55555, C12N 15/88Filed as BioNTech SE2025-06-20Steffen Panzner | pending |
| METHODS OF TREATING PANCREATIC CANCER WITH A PD-1 AXIS BINDING ANTAGONIST AND AN RNA VACCINEA61K 39/001111, A61K 39/0011, A61P 35/00, A61K2039/852, A61K 33/243, A61K2239/54, A61K 9/0019, A61K 9/1272, A61K 9/5123, A61K 31/337, A61K 31/475, A61K 31/513, A61K 31/519, A61K 31/555, A61K 39/39558, A61K 45/06, A61K2039/505, A61K2039/53, A61K2039/54, A61K2039/545, A61K2039/555, A61K2039/55516, A61K2039/55555, A61K2039/6018, A61K2300/00, C07K 14/70539, C07K 16/2818, C07K 16/2827, C07K2317/565, C07K2319/02, C12Q 1/6886, C12Q2600/106, C12Q2600/156, A61K 39/12Filed as BioNTech SE2025-06-18Michael Robert MANCUSO | pending |
| COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMAFiled as BIONTECH SE2025-06-17UGUR SAHIN | pending |
| RNA CAPPING EFFICIENCY ASSAYC07H 19/16, C12Q 1/6806, C12N 9/22, C12Y 301/26005, C12Q2521/301Filed as BioNTech SE2025-05-13Maximilian Buff | pending |
| NUCLEIC ACID COMPLEXES AND USES THEREOFA61K 47/549, A61K 47/645, A61K 47/59Filed as BioNTech SE2025-04-18Jorge Moreno Herrero | pending |
| METHODS AND USES ASSOCIATED WITH LIQUID COMPOSITIONSA61K 9/5192, A61K 9/5123, A61K 31/7105Filed as BioNTech SE2025-04-17Christian REINSCH | pending |
| IN VITRO TRANSCRIPTION TECHNOLOGIESA61P 31/14, C12P 19/34, C12N 9/1247, C12N 15/111, C12N2330/30Filed as BioNTech SE2025-04-11Irena Rabe | pending |
| RNA COMPOSITIONS TARGETING CLAUDIN-18.2C07K 16/28, A61P 35/00, A61K 9/0019, A61K 9/5123, A61K 9/5146, A61K 45/06, A61K 48/0041, A61K 48/005, A61K 48/0075, C07K2317/732, C07K2317/734, C07K2317/92Filed as BioNTech SE2025-04-04Ugur Sahin | pending |
| RNA COMPOSITIONS FOR DELIVERY OF ORTHOPOX ANTIGENS AND RELATED METHODSFiled as BIONTECH SE2025-04-04ADAM ZUIANI | pending |
| RNA CONSTRUCTS AND USES THEREOFC07H 21/02, A61K 31/7088, C12N 15/67Filed as BioNTech SE2025-04-01Gábor Boros | pending |
| NUCLEIC ACID COMPLEXES AND USES THEREOFA61K 47/59, A61K 9/5123, A61K 47/62, A61K 47/64, A61K 47/6935, A61K 31/7105, A61K 47/22, A61K 47/26, A61K 48/0041, B82Y 5/00, C12N 15/67, C12N 15/88Filed as BioNTech SE2025-03-25Jorge Moreno Herrero | pending |
| COMPOSITIONS FOR DELIVERY OF PLASMODIUM CSP ANTIGENS AND RELATED METHODSA61P 33/06, A61K 39/015, A61P 37/04, Y02A 50/30, A61K2039/53, A61K2039/572, A61K2039/575, A61K2039/6075, A61K2039/6093, C07K 14/445Filed as BioNTech SE2025-03-21Ugur Sahin | pending |
| COMPOSITIONS FOR DELIVERY OF LIVER STAGE ANTIGENS AND RELATED METHODSA61K 39/015, A61P 33/06, Y02A 50/30, A61K2039/53, A61K2039/55555, A61K2039/572, C07K 14/005, C07K 14/445, C07K2319/00, C07K2319/03, C12N2710/16622, C12N2710/16634Filed as BioNTech SE2025-03-21Asaf Poran | pending |
| SYSTEMS AND METHODS FOR MACHINE LEARNING-BASED GENOME ANNOTATIONG16B 20/30, G06N 3/123, G16B 40/30, G16B 40/20, G16B 30/00Filed as BioNTech SE2025-03-10Thomas Pierrot | pending |
| SYSTEMS AND METHODS FOR MULTIMODAL CONVERSATIONAL AGENTS FOR BIOLOGICAL SEQUENCE ANALYSISG16B 30/00, G16B 40/30, G06N 3/0455Filed as BioNTech SE2025-03-10Thomas Pierrot | pending |
| ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOFA61K 39/00, C07K 16/28, C07K 16/2878, A61P 35/00, A61K2039/505, C07K 16/4241, C07K2317/24, C07K2317/31, C07K2317/33, C07K2317/35, C07K2317/52, C07K2317/565, C07K2317/71, C07K2317/73, C07K2317/75, C07K2317/92Filed as BioNTech SE2025-02-25Kristel Kemper | pending |
| ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOFA61K 39/00, C07K 16/28, C07K 16/2878, A61P 35/00, A61K2039/505, C07K 16/4241, C07K2317/24, C07K2317/31, C07K2317/33, C07K2317/35, C07K2317/52, C07K2317/565, C07K2317/71, C07K2317/73, C07K2317/75, C07K2317/92Filed as BioNTech SE2025-02-25Kristel Kemper | pending |
| CORONAVIRUS VACCINEFiled as BIONTECH SE2025-02-21KENA ANNE SWANSON | pending |
| RNA FOR PREVENTING OR TREATING TUBERCULOSISA61K 39/04, A61P 37/04, A61P 31/06, A61K 9/0019, A61K2039/53, A61K2039/54, A61K2039/545, A61K2039/55555, A61K2039/572, A61K2039/575, A61K2039/6018, A61K2039/605, A61K2039/645, A61K2039/70Filed as BIONTECH SE2025-01-31Neha AGRAWAL | pending |
| NUCLEIC ACID COMPOSITIONS INCLUDING AMPHIPHILIC OLIGO ETHYLENE GLYCOL (OEG)-CONJUGATED COMPOUNDS AND METHODS OF USING SUCH COMPOUNDS AND COMPOSITIONSA61K 48/0008, A61K 47/58, A61K 9/5146, A61K 47/34Filed as BIONTECH SE2025-01-28Zhengxin DONG | pending |
| MULTIFUNCTIONAL CELLS TRANSIENTLY EXPRESSING AN IMMUNE RECEPTOR AND ONE OR MORE CYTOKINES, THEIR USE AND METHODS FOR THEIR PRODUCTIONA61K 40/11, A61P 35/00, A61K2239/47, A61K 40/35, A61K 40/4224, A61K 40/4202, A61K 40/31, C07K 14/5434, C07K 14/56, C07K 14/7051, C07K 16/2851, C07K2319/03, C12N 5/0638, C12N2510/00, A61K2300/00Filed as BioNTech SE2025-01-16Ugur SAHIN | pending |
| HUMANISED ANTIBODIES OR FUNCTIONAL FRAGMENTS THEREOF AGAINST TUMOUR ANTIGENSC07K 16/2896, C07K 16/30, C07K 16/3076, A61K 47/6851, A61K 47/6803, A61P 35/00, G01N 33/575, G01N 33/5759, A61K 39/3955, A61K 48/005, A61K2039/505, C07K 16/3092, C07K2317/24, C07K2317/565, C07K2317/77, C07K2317/92Filed as BioNTech SE2024-12-24Nuno José Prego Ramos | pending |
| METHODS FOR PREDICTING THE USEFULNESS OF DISEASE SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPYG01N 33/68, G01N 33/6893, A61P 35/00, A61K 39/001156, A61K 39/001188, A61K2039/876, A61K 40/4245, A61K 40/4269, A61K 39/0011, A61K2039/53, A61K2039/70, A61K2121/00, A61K2300/00, G01N2333/70514, G01N2333/70517, G01N2800/52Filed as BioNTech SE2024-12-20Ugur Sahin | pending |
| COMPLEXES FOR DELIVERY OF NUCLEIC ACIDSA61K 48/0041, A61K 48/0058Filed as BioNTech SE2024-11-26Jorge Moreno Herrero | pending |
| RNA COMPOSITIONS FOR DELIVERY OF MONKEYPOX ANTIGENS AND RELATED METHODSA61K 39/12, A61K 39/275, A61K 39/285, A61P 31/20, A61K2039/53, A61K2039/55555, A61K2039/70, C07K 14/005, C12N2710/24134Filed as BioNTech SE2024-11-25Asaf Poran | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on BNTX
Company overviewEverything on BNTX in one place, with the price.SEC filingsWhat BNTX's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat BNTX's own officers and directors buy and sell.Who owns itEvery manager reporting a position in BNTX.Funds holding itWhich funds and ETFs hold BNTX, and how big a bet.